Certara, Inc. (CERT)
Largest Insider Buys in Sector
CERT Stock Price History Chart
CERT Stock Performance
About Certara, Inc.
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic …
Insider Activity of Certara, Inc.
Over the last 12 months, insiders at Certara, Inc. have bought $0 and sold $1.3M worth of Certara, Inc. stock.
On average, over the past 5 years, insiders at Certara, Inc. have bought $998,243 and sold $552.95M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,807 shares for transaction amount of $75,951 was made by BROSHY ERAN (director) on 2023‑08‑22.
List of Insider Buy and Sell Transactions, Certara, Inc.
| 2024-10-07 | Sale | PRESIDENT, DRUG DEV SOLUTIONS | 5,409 0.0035% | $11.03 | $59,661 | -0.45% | ||
| 2024-09-09 | Sale | PRESIDENT, CHIEF COMMERCAL OFF | 51,224 0.0313% | $11.29 | $578,319 | -3.84% | ||
| 2024-04-02 | Sale | PRESIDENT, DRUG DEV SOLUTIONS | 14,427 0.009% | $16.85 | $243,161 | -22.89% | ||
| 2024-04-01 | Sale | SVP AND GENERAL COUNSEL | 3,000 0.0019% | $18.00 | $54,000 | -27.14% | ||
| 2024-03-04 | Sale | SVP AND GENERAL COUNSEL | 3,000 0.0018% | $18.28 | $54,840 | -23.89% | ||
| 2024-02-20 | Sale | PRESIDENT, DRUG DEV SOLUTIONS | 5,000 0.0032% | $18.00 | $90,000 | -12.46% | ||
| 2024-02-12 | Sale | SVP AND GENERAL COUNSEL | 6,000 0.0038% | $18.00 | $108,000 | -13.30% | ||
| 2023-12-26 | Sale | SVP AND GENERAL COUNSEL | 6,000 0.0037% | $18.00 | $108,000 | -11.98% | ||
| 2023-09-11 | Sale | PRESIDENT, CHIEF COMMERCAL OFF | 51,224 0.0321% | $14.60 | $747,870 | +11.26% | ||
| 2023-08-22 | director | 4,807 0.003% | $15.80 | $75,951 | +3.68% | |||
| 2023-08-21 | director | 193 0.0001% | $16.10 | $3,107 | +0.84% | |||
| 2023-06-05 | Sale | PRESIDENT, INTEGRATED DRUG DEV | 19,104 0.0122% | $21.55 | $411,691 | -21.90% | ||
| 2023-05-11 | Sale | SVP AND GENERAL COUNSEL | 5,000 0.0031% | $20.82 | $104,100 | -19.51% | ||
| 2023-04-14 | Sale | SVP AND GENERAL COUNSEL | 5,000 0.0031% | $23.66 | $118,300 | -29.51% | ||
| 2023-03-06 | Sale | SVP AND GENERAL COUNSEL | 10,000 0.0063% | $21.45 | $214,500 | -20.08% | ||
| 2023-02-02 | Sale | SVP AND GENERAL COUNSEL | 15,000 0.0094% | $20.00 | $300,000 | -13.49% | ||
| 2022-12-08 | Sale | director | 29.95M 15.9478% | $15.00 | $449.32M | +0.53% | ||
| 2022-11-22 | Sale | PRESIDENT, SOFTWARE | 51,223 0.0322% | $15.55 | $796,518 | +14.60% | ||
| 2022-11-15 | Sale | director | 245,793 0.1555% | $15.57 | $3.83M | +15.12% | ||
| 2022-11-14 | Sale | director | 4,207 0.0028% | $15.27 | $64,241 | +22.51% |
Insider Historical Profitability
| Traynor Richard M. | SVP AND GENERAL COUNSEL | 173524 0.1078% | $10.70 | 1 | 21 | <0.0001% |
| Schemick Michael Andrew | CHIEF FINANCIAL OFFICER | 517870 0.3217% | $10.70 | 1 | 6 | +7.65% |
| CASHMAN JAMES E III | director | 438782 0.2726% | $10.70 | 1 | 2 | <0.0001% |
| WALSH MATTHEW M | director | 167901 0.1043% | $10.70 | 1 | 1 | <0.0001% |
| McLean Stephen M. | 42000 0.0261% | $10.70 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $250.12M | 8.7 | 13.99M | +0.23% | +$576,004.20 | 0.01 | |
| The Vanguard Group | $224.49M | 7.81 | 12.56M | +0.09% | +$193,461.60 | <0.01 | |
| Baillie Gifford Co | $152.65M | 5.31 | 8.54M | -4.3% | -$6.86M | 0.12 | |
| William Blair Investment Management | $102.27M | 3.56 | 5.72M | -18.78% | -$23.65M | 0.26 | |
| Wasatch Advisors | $88.06M | 3.06 | 4.92M | +23.36% | +$16.67M | 0.46 |